This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ferric citrate: A Synthesis of Findings from 23 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ferric citrate: A Synthesis of Findings from 23 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Ferric citrate is an oral iron product approved for the treatment of iron deficiency anemia and as a phosphate binder for chronic kidney disease (CKD). Several studies have investigated the effects of ferric citrate, with a focus on its effectiveness and safety. 1 investigated whether gastric acid secretion inhibitors (GASIs) influenced the iron absorption and phosphate-lowering effects of ferric citrate in CKD patients. The study found that GASIs did not influence these effects. This suggests that ferric citrate's benefits might not be hindered by commonly used medications for gastrointestinal issues.

In a different context, 17 explored the interaction of proton pump inhibitors (PPIs) with three phosphate binders, including ferric citrate, in hemodialysis patients. It found that PPIs did not hinder the phosphate-lowering effects of ferric citrate or sucroferric oxyhydroxide, while they did impact the effectiveness of lanthanum carbonate. This further suggests that ferric citrate might be a reliable option for managing phosphate levels even when patients are taking PPIs.

Beyond its effects on iron and phosphate, 4 explored the potential renoprotective effects of ferric citrate in a mouse model of CKD. The study observed a reduction in serum phosphate concentrations, an increase in serum iron levels, and a significant decrease in circulating fibroblast growth factor 23 levels. Furthermore, ferric citrate demonstrated benefits in reducing systemic inflammation, improving kidney function, and decreasing albuminuria and kidney fibrosis. This suggests a potential for ferric citrate to protect the kidneys in CKD.

Diving deeper into the absorption mechanism, 6 confirmed that enteral ferric citrate absorption relies on the iron transport protein ferroportin. This discovery sheds light on the underlying process of how ferric citrate delivers iron into the body.

The potential of ferric citrate to combat vascular calcification, a significant contributor to cardiovascular disease in CKD, was investigated in 23 . The study found that ferric citrate can arrest further calcium deposition in high-phosphate calcified vascular smooth muscle cells. This effect was achieved through an anti-apoptotic action and the induction of autophagy, suggesting a potential role for ferric citrate in preventing the progression of vascular calcification.

2 explored the complex interplay between iron utilization and FGF23 in a mouse model of CKD. The study found that while FGF23 is a protective factor in mineral metabolism, ferric citrate was responsible for maintaining serum iron levels and correcting inflammatory mediators. This suggests that ferric citrate may offer additional benefits beyond its direct effects on iron and phosphate.

A systematic review and meta-analysis of RCTs in 15 evaluated the impact of iron supplementation on FGF23 levels in CKD patients with iron deficiency anemia. The results revealed a significant decrease in FGF23 levels with iron treatment compared to placebo. Oral iron therapy showed a greater reduction in FGF23 levels than intravenous iron therapy. This further supports the potential role of iron in managing FGF23 levels in CKD.

The broader context of phosphate binders in CKD was addressed in 22 . This narrative review summarized recent data on various phosphate binders, including ferric citrate, highlighting their potential impact on cardiovascular mortality and morbidity, adherence to therapy, and new developments in the field.

Focusing on the application of ferric citrate in Japanese patients with iron deficiency anemia, 7 evaluated its efficacy and safety. The study found that both doses of ferric citrate (500 and 1,000 mg/day) improved anemia and iron deficiency conditions, leading to sufficient iron repletion in most patients. No safety concerns were identified, suggesting its potential as a novel oral iron preparation for this population.

Further exploring ferric citrate's potential as an iron preparation, 13 compared it to sodium ferrous citrate in a randomized, double-blind, phase 3 non-inferiority study. The study found that ferric citrate was non-inferior to sodium ferrous citrate in terms of hemoglobin concentration increase. Importantly, ferric citrate demonstrated significantly lower incidences of nausea and vomiting, making it a potentially more tolerable option for patients with iron deficiency anemia.

A comprehensive review in 14 discussed the evolution of iron therapy in CKD, highlighting the emergence of ferric citrate as a safe and effective phosphate binder. The review also explored the advantages of new-generation IV iron preparations and the use of ferric pyrophosphate citrate in hemodialysis patients. This review highlights the evolving landscape of iron management in CKD, with ferric citrate playing a significant role.

Investigating the iron kinetics following treatment with ferric citrate and sucroferric oxyhydroxide, 19 compared their iron uptake and tissue accumulation in different rat models. The study aimed to understand the differences in iron absorption from these agents. These insights contribute to the understanding of how these phosphate binders manage iron levels in the body.

A potential risk associated with ferric citrate was highlighted in 21 , which reported cases of iron overload in peritoneal dialysis patients receiving ferric citrate. This finding emphasizes the importance of close monitoring of iron studies and suggests that a lower maximum dose might be necessary for this patient group.

Moving beyond its medical applications, 16 explored the use of ferric citrate in food packaging. The study developed an edible sturgeon skin gelatine film containing esculin and ferric citrate to prevent contamination by Enterococcus faecalis. The film changes color in the presence of this bacteria, offering a potential method for detecting food spoilage.

Ferric ammonium citrate, a more dissolvable form of ferric citrate, was investigated for its effects on osteoblast proliferation and differentiation in 8 . The study found that it inhibited these processes, potentially contributing to osteoporosis. However, soybean-derived peptides were shown to reverse these effects. This finding suggests a potential for dietary interventions to mitigate any negative effects of ferric ammonium citrate on bone health.

An interesting study on rats in 20 explored the effects of ferric citrate on iron deficiency anemia and phosphorus metabolism. The study found that ferric citrate could improve anemia without affecting phosphorus metabolism, suggesting its potential as a treatment for iron deficiency anemia in patients without CKD.

The impact of macrophage polarization on iron metabolism was investigated in 11 . The study found that M1 macrophages tend to lock iron in the cell, reducing extracellular iron content and inhibiting bacterial growth, while M2 macrophages tend to excrete iron, promoting cell proliferation and tissue repair. This highlights the important role of macrophages in iron regulation and suggests potential implications for infection and tissue healing.

A potential mechanism for the anticancer activity of ferric ammonium citrate was investigated in 12 . The study found that ferric ammonium citrate induced ferroptosis in non-small-cell lung carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity. This finding suggests a potential new therapeutic strategy for treating this type of cancer.

The long-term safety and efficacy of ferric citrate in hemodialysis patients was investigated in 5 . The study found that ferric citrate demonstrated long-term safety and efficacy in lowering phosphate levels and repleting iron stores in hemodialysis patients. This suggests that ferric citrate might be a suitable long-term treatment option for this patient group.

A meta-analysis in 18 investigated the efficacy and safety of ferric citrate in managing hyperphosphatemia and iron deficiency anemia in CKD patients. The study found that ferric citrate was effective in controlling both conditions, highlighting its potential for a combined therapeutic approach.

The long-term efficacy and safety of ferric citrate hydrate and sucroferric oxyhydroxide, two iron-based phosphate binders, were investigated in 10 . The study highlighted the need for further research to fully understand the long-term effects of these agents on hemodialysis patients. This underscores the ongoing need for research to ensure the safe and effective use of these medications over extended periods.

Benefits and Risks

Benefit Summary

Ferric citrate has shown potential benefits in managing iron deficiency anemia and hyperphosphatemia in CKD patients. It can improve iron levels and reduce phosphate levels, potentially leading to improved overall health and quality of life. Furthermore, it has demonstrated renoprotective effects in animal models, suggesting a potential role in slowing the progression of CKD. Additionally, it has been shown to be effective and safe for long-term use in hemodialysis patients, making it a viable treatment option for this specific patient population. It also has shown to have lower risk of gastrointestinal side effects compared to other iron preparations.

Risk Summary

While promising, ferric citrate can pose potential risks. Iron overload has been reported in peritoneal dialysis patients, highlighting the importance of close monitoring of iron levels in this specific population. Ferric citrate might also have negative effects on bone health by inhibiting osteoblast proliferation and differentiation, a potential concern for long-term use.

Comparison Across Studies

Commonalities Across Studies

Multiple studies have consistently shown that ferric citrate is an effective treatment for iron deficiency anemia and hyperphosphatemia in CKD patients. The studies also indicate that ferric citrate is generally well-tolerated, with a lower risk of gastrointestinal side effects compared to other iron preparations. This consistent evidence suggests that ferric citrate is a promising treatment option for CKD patients.

Differences Across Studies

While many studies agree on the benefits of ferric citrate, there are some discrepancies. Some studies have shown that ferric citrate is unaffected by gastric acid secretion inhibitors, while others have found that it might have a reduced effect when combined with PPIs. Further research is needed to understand the complex interactions between ferric citrate and various medications. The potential for iron overload in peritoneal dialysis patients was also highlighted in one study, suggesting the need for closer monitoring in this specific population. More research is also needed to understand the long-term safety and efficacy of ferric citrate in various patient groups.

Consistency and Contradictions in Findings

The research on ferric citrate presents a generally consistent picture of its benefits in managing iron deficiency anemia and hyperphosphatemia in CKD patients. However, some contradictions exist. While most studies show that ferric citrate is generally safe and well-tolerated, one study highlighted the potential for iron overload in peritoneal dialysis patients. This contradiction emphasizes the importance of individualizing treatment strategies and closely monitoring iron levels in specific populations. Additional research is crucial to understand the nuances of ferric citrate's effects and ensure its safe and effective use.

Application in Real-Life Settings: Points to Consider

Ferric citrate holds potential for managing iron deficiency anemia and hyperphosphatemia in CKD patients. However, it's important to remember that every patient is unique. Before starting treatment, a thorough discussion with your healthcare provider is crucial. This includes understanding your individual risks and benefits, as well as potential interactions with other medications you might be taking. It is also vital to have regular blood tests to monitor iron levels, especially if you are on peritoneal dialysis. This proactive approach ensures safe and effective treatment.

Limitations of Current Research

Despite the promising findings, current research on ferric citrate still has limitations. Long-term studies are crucial to understand the long-term safety and efficacy of ferric citrate. Additionally, more research is needed to understand the complex interactions between ferric citrate and various medications and conditions. Further research is also required to understand the optimal dosage and administration of ferric citrate for different patient populations. Addressing these limitations will contribute to a more comprehensive understanding of ferric citrate's benefits and risks.

Future Research Directions

Future research should focus on addressing the limitations of current research. Long-term studies are needed to evaluate the long-term safety and efficacy of ferric citrate in various patient groups. The interactions between ferric citrate and other medications should be investigated thoroughly to optimize treatment strategies. More research is needed to optimize the dosage and administration of ferric citrate for different patient groups. Additionally, research exploring the potential of ferric citrate in preventing the progression of CKD and in managing vascular calcification would be valuable. Understanding the underlying mechanisms of ferric citrate's effects on iron metabolism and its potential impact on other organ systems is also essential. By addressing these research questions, a more comprehensive understanding of ferric citrate's role in managing CKD and iron deficiency anemia can be achieved.

Conclusion

Ferric citrate is a promising treatment option for iron deficiency anemia and hyperphosphatemia in CKD patients. It is generally safe and well-tolerated, but close monitoring of iron levels, particularly in peritoneal dialysis patients, is crucial. Further research is needed to understand its long-term effects and interactions with other medications. However, the existing evidence suggests that ferric citrate might play a significant role in improving the health and well-being of CKD patients.


Literature analysis of 23 papers
Positive Content
23
Neutral Content
0
Negative Content
0
Article Type
2
2
2
3
23

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Chinese


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.